To observe the effects of empagliflozin tablets-assisted therapy on end-diastolic volume and major cardiovascular adverse events in patients with mild reduced EF heart failure (HFmrEF).

Patients with HFmrEF were divided into control group and treatment group by queue method. The control group received conventional treatment. The treatment group was given empagliflozin tablets in addition to control group, 10 mg each time (starting dose and target dose were both 10 mg), orally on an empty stomach in the morning, once a day. Both groups of patients were treated for 6 months. The clinical efficacy, end-diastolic volume including left ventricular end-diastolic area (LVEDA) and left ventricular end-diastolic volume (LVEDV), left ventricular ejection fraction (LVEF), myocardial markers including cardiac troponin I (cTnI) and N-terminal B-type natriuretic peptide (NT-proBNP), major adverse cardiovascular events and safety were compared between the two groups.

Both groups had no cases dropped out, with 60 cases in control group and 60 cases in treatment group. After treatment, the total effective rates of treatment group and control group were 95.00% (57 cases/60 cases) and 81.67% (49 cases/60 cases), respectively, with statistically significant difference (P<0.05). After treatment, the LVEF of treatment group and control group were (56.20±5.12)% and (50.25±4.26)%, LVEDV were (142.58±15.58) and (165.28±18.59) mL, LVEDA were (36.28±3.41) and (39.62±3.56) cm², serum NT-proBNP levels were (869.48±135.29) and (1 459.87±158.69) pg·mL^-1, cTnI levels were (7.02±1.65) and (9.28±1.74) ng·L^-1, respectively, and the incidence of major cardiovascular adverse events in treatment group and control group were 5.00% and 16.67%. The above indexes in treatment group had statistical significant differences compared with control group (all P<0.05). The adverse drug reactions of treatment group mainly include headache, hyperkalemia, hypotension and gastrointestinal reactions, while the adverse drug reactions of control group mainly include hyperkalemia, headache and hypotension. During the treatment, the incidence of adverse drug reactions in treatment group and control group were 8.33% and 5.00%, respectively (P>0.05).

Adjuvant treatment with empagliflozin tablets can improve the overall therapeutic effect of HFmrEF, improve the end diastolic volume index and LVEF of patients, regulate myocardial marker indicators, reduce the incidence of major cardiovascular adverse events, and has good safety.